Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multi-centric, Open-label, Comparator-controlled Study to evaluate the efficacy and safety of RABIMABs administered in conjunction with Vaxirab N for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

Next Previous
Trial Profile

Randomized, Multi-centric, Open-label, Comparator-controlled Study to evaluate the efficacy and safety of RABIMABs administered in conjunction with Vaxirab N for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docaravimab/miromavimab (Primary) ; Docaravimab/miromavimab (Primary) ; Rabies immune globulin
  • Indications Rabies
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Cadila Healthcare

    • Most Recent Events

    • 17 Jun 2020 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2020 Primary endpoint (a. Proportion of subjects with RFFIT titre more than or equal to 0.5 IU/ml on Days 14 who receiving RABIMABs + Vaxirab N and Immunoglobulins (Imogam) + Vaxirab N) has been met according to the results published in the Clinical Infectious Diseases
    • 17 Jun 2020 Results published in the Clinical Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top